In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker - Wang - 2020 - Cancer Medicine - Wiley Online Library
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | Journal for ImmunoTherapy of Cancer | Full Text
PD-1 and PD-L1 inhibitors - Wikipedia
Opdualag Approved to Treat Advanced Melanoma - NCI
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
A PD 1 Inhibitor Fairy Tale - YouTube
PD-1/PD-L1 inhibitor 2(BMS-202)_ImmunoWay Biotechnology Company |抗体|病理抗体|诊断抗体
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action - Willsmore - 2021 - European Journal of Immunology - Wiley Online Library
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway | Acta Pharmacologica Sinica
Immune Checkpoint Inhibitors - NCI
BMS-1 (PD-1/PD-L1 inhibitor 1) | PD-1/PD-L1 PPI Inhibitor | MedChemExpress
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
Current issues and perspectives in PD-1 blockade cancer immunotherapy | SpringerLink
The diverse functions of the PD1 inhibitory pathway | Nature Reviews Immunology
Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment | Journal for ImmunoTherapy of Cancer
Frontiers | Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
IMMUNTERAPI
In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors
Do Checkpoint Inhibitors Increase Rejection Risk? - Division of Nephrology
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation | Journal of Medicinal Chemistry
Current Oncology | Free Full-Text | Immune Checkpoint Inhibitors in Cancer Therapy
Frontiers | PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?
Immune checkpoint blockade in HIV - eBioMedicine
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | NEJM
